- Home
- JBDI vs MRKR Comparison
JBDI vs MRKR Comparison
Compare JBDI & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBDI
- MRKR
- Stock Information
- Founded
- JBDI 1983
- MRKR N/A
- Country
- JBDI Singapore
- MRKR United States
- Employees
- JBDI N/A
- MRKR N/A
- Industry
- JBDI
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- JBDI
- MRKR Health Care
- Exchange
- JBDI Nasdaq
- MRKR Nasdaq
- Market Cap
- JBDI 19.0M
- MRKR 19.1M
- IPO Year
- JBDI 2024
- MRKR N/A
- Fundamental
- Price
- JBDI $0.95
- MRKR $1.56
- Analyst Decision
- JBDI
- MRKR Strong Buy
- Analyst Count
- JBDI 0
- MRKR 3
- Target Price
- JBDI N/A
- MRKR $13.17
- AVG Volume (30 Days)
- JBDI 36.8K
- MRKR 3.4M
- Earning Date
- JBDI 02-15-2025
- MRKR 08-13-2025
- Dividend Yield
- JBDI N/A
- MRKR N/A
- EPS Growth
- JBDI N/A
- MRKR N/A
- EPS
- JBDI N/A
- MRKR N/A
- Revenue
- JBDI $9,017,000.00
- MRKR $5,696,123.00
- Revenue This Year
- JBDI N/A
- MRKR N/A
- Revenue Next Year
- JBDI N/A
- MRKR $7.16
- P/E Ratio
- JBDI N/A
- MRKR N/A
- Revenue Growth
- JBDI N/A
- MRKR 71.53
- 52 Week Low
- JBDI $0.49
- MRKR $0.95
- 52 Week High
- JBDI $39.41
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- JBDI N/A
- MRKR 49.21
- Support Level
- JBDI N/A
- MRKR $1.41
- Resistance Level
- JBDI N/A
- MRKR $1.65
- Average True Range (ATR)
- JBDI 0.00
- MRKR 0.33
- MACD
- JBDI 0.00
- MRKR -0.02
- Stochastic Oscillator
- JBDI 0.00
- MRKR 5.64
About JBDI JBDI Holdings Limited Ordinary Shares
JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. Its products include Reconditioned and new steel drums, plastic drums, carboys and IBCs.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.